MX2018013347A - Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. - Google Patents
Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.Info
- Publication number
- MX2018013347A MX2018013347A MX2018013347A MX2018013347A MX2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A
- Authority
- MX
- Mexico
- Prior art keywords
- hair loss
- deuterated
- treatment
- loss disorders
- jak inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Abstract
Se describe un método para tratar trastornos de pérdida del cabello en un sujeto que se tratan de manera beneficiosa administrando un inhibidor de JAK1 y/o JAK2. El método comprende administrar al sujeto una cantidad en el intervalo de aproximadamente 4 mg a aproximadamente SO mg del Compuesto (I): VER FÓRMULA Compuesto (1) o una sal farmacéuticamente aceptable de este. Esta invención también proporciona composiciones que comprende el Compuesto (I) y el uso de tales composiciones en los métodos descritos.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662331827P | 2016-05-04 | 2016-05-04 | |
US201662338869P | 2016-05-19 | 2016-05-19 | |
US201662418774P | 2016-11-07 | 2016-11-07 | |
US201662419237P | 2016-11-08 | 2016-11-08 | |
US201662434404P | 2016-12-14 | 2016-12-14 | |
US201762466358P | 2017-03-02 | 2017-03-02 | |
US201762492758P | 2017-05-01 | 2017-05-01 | |
PCT/US2017/031142 WO2017192905A1 (en) | 2016-05-04 | 2017-05-04 | Treatment of hair loss disorders with deuterated jak inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018013347A true MX2018013347A (es) | 2019-09-02 |
Family
ID=60203616
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018013347A MX2018013347A (es) | 2016-05-04 | 2017-05-04 | Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002323A MX2023002323A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002325A MX2023002325A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2021014175A MX2021014175A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002321A MX2023002321A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002324A MX2023002324A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002323A MX2023002323A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002325A MX2023002325A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2021014175A MX2021014175A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002321A MX2023002321A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002324A MX2023002324A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
Country Status (10)
Country | Link |
---|---|
US (2) | US10561659B2 (es) |
EP (1) | EP3452039A4 (es) |
JP (2) | JP7145080B2 (es) |
KR (2) | KR20230086814A (es) |
CN (1) | CN109069493A (es) |
AU (2) | AU2017261286B2 (es) |
BR (1) | BR112018072339A2 (es) |
CA (1) | CA3022519A1 (es) |
MX (6) | MX2018013347A (es) |
WO (1) | WO2017192905A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
WO2022094133A1 (en) | 2020-10-28 | 2022-05-05 | Concert Pharmaceuticals, Inc. | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
CN112402615A (zh) * | 2020-11-11 | 2021-02-26 | 长沙晶易医药科技有限公司 | 一种用于治疗斑秃的复方外用制剂及其制备方法 |
WO2023018904A1 (en) | 2021-08-11 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
AU2022328282A1 (en) | 2021-08-12 | 2024-02-22 | Sun Pharmaceutical Industries, Inc. | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
WO2023215520A1 (en) | 2022-05-04 | 2023-11-09 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
DE60201988T2 (de) | 2001-05-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Pharmazeutische dosierungsform von amorphem nilfenavir mesylat |
US20060094744A1 (en) | 2004-09-29 | 2006-05-04 | Maryanoff Cynthia A | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
DK2455382T3 (da) | 2005-12-13 | 2017-01-02 | Incyte Holdings Corp | Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer |
RS60205B1 (sr) | 2005-12-28 | 2020-06-30 | Vertex Pharma | Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
PL2635299T3 (pl) * | 2010-11-02 | 2020-03-31 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
DK2830662T3 (da) | 2012-03-29 | 2019-01-02 | Univ Columbia | Fremgangsmåder til behandlng af hårtabsforstyrrelser |
US20150197525A1 (en) | 2012-06-15 | 2015-07-16 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
ES2682043T3 (es) * | 2012-07-30 | 2018-09-18 | Concert Pharmaceuticals Inc. | Ibrutinib deuterado |
EP2919766B1 (en) | 2012-11-15 | 2021-05-26 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
CN104725380B (zh) * | 2013-12-18 | 2019-06-28 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
MX2016010213A (es) * | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
-
2017
- 2017-05-04 CA CA3022519A patent/CA3022519A1/en active Pending
- 2017-05-04 KR KR1020237019001A patent/KR20230086814A/ko not_active Application Discontinuation
- 2017-05-04 WO PCT/US2017/031142 patent/WO2017192905A1/en active Application Filing
- 2017-05-04 EP EP17793380.1A patent/EP3452039A4/en active Pending
- 2017-05-04 US US16/098,338 patent/US10561659B2/en active Active
- 2017-05-04 CN CN201780027427.2A patent/CN109069493A/zh active Pending
- 2017-05-04 BR BR112018072339-8A patent/BR112018072339A2/pt active Search and Examination
- 2017-05-04 KR KR1020187034867A patent/KR20190003711A/ko active Application Filing
- 2017-05-04 MX MX2018013347A patent/MX2018013347A/es unknown
- 2017-05-04 AU AU2017261286A patent/AU2017261286B2/en active Active
- 2017-05-04 JP JP2018557837A patent/JP7145080B2/ja active Active
-
2018
- 2018-10-31 MX MX2023002323A patent/MX2023002323A/es unknown
- 2018-10-31 MX MX2023002325A patent/MX2023002325A/es unknown
- 2018-10-31 MX MX2021014175A patent/MX2021014175A/es unknown
- 2018-10-31 MX MX2023002321A patent/MX2023002321A/es unknown
- 2018-10-31 MX MX2023002324A patent/MX2023002324A/es unknown
-
2019
- 2019-12-05 US US16/704,402 patent/US20200222408A1/en active Pending
-
2022
- 2022-09-16 JP JP2022147751A patent/JP2022171838A/ja active Pending
-
2023
- 2023-02-24 AU AU2023201112A patent/AU2023201112A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7145080B2 (ja) | 2022-09-30 |
AU2023201112A1 (en) | 2023-03-30 |
AU2017261286B2 (en) | 2023-03-23 |
KR20190003711A (ko) | 2019-01-09 |
CN109069493A (zh) | 2018-12-21 |
CA3022519A1 (en) | 2017-11-09 |
US20200222408A1 (en) | 2020-07-16 |
EP3452039A4 (en) | 2019-12-25 |
KR20230086814A (ko) | 2023-06-15 |
JP2019516684A (ja) | 2019-06-20 |
MX2023002323A (es) | 2023-03-22 |
MX2023002324A (es) | 2023-03-22 |
US20190160068A1 (en) | 2019-05-30 |
EP3452039A1 (en) | 2019-03-13 |
JP2022171838A (ja) | 2022-11-11 |
BR112018072339A2 (pt) | 2019-02-19 |
US10561659B2 (en) | 2020-02-18 |
MX2023002325A (es) | 2023-03-22 |
MX2021014175A (es) | 2022-01-04 |
WO2017192905A1 (en) | 2017-11-09 |
AU2017261286A1 (en) | 2018-11-22 |
MX2023002321A (es) | 2023-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002321A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
EA202190630A1 (ru) | Способы комбинированной терапии | |
PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
EA202092343A1 (ru) | Лечение гнойного гидраденита с использованием ингибиторов jak | |
MX2021002521A (es) | Dimetilaminoazetidinaminas como inhibidores de jak. | |
MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
MX2022001004A (es) | Inhibidores de enzimas. | |
MX2021007260A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales. | |
AU2024201828A1 (en) | Methods of treating and/or preventing actinic keratosis | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
MX2021013602A (es) | Inhibidores de jak. | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
EA201892098A1 (ru) | Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
MX2021011986A (es) | Metodos de tratamiento de dolor neuropatico. | |
MX2020008413A (es) | Composiciones para la prevencion o tratamiento de la uveitis. | |
MX2023005027A (es) | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. |